ISDA

Entry Detail

PDB ID:

5T1T

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Irak4 kinase - compound 1 co-structure

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2016-08-22

Release Date:

2017-05-03

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.34 Å

R-Value Free:

0.22

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Interleukin-1 receptor-associated kinase 4
Chain IDs:A, B, C, D
Chain Length:301
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:Q9NWZ3 Pfam ID:PF07714

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
SEP	A	SER	modified residue
TPO	A	THR	modified residue

Ligand Molecules

76P

Primary Citation

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.

Smith, G.F, Altman, M.D, Andresen, B, Baker, J, Brubaker, J.D, Chen, H, Chen, Y, Childers, M, Donofrio, A, Ferguson, H, Fischer, C, Fischmann, T.O, Gibeau, C, Hicks, A, Jin, S, Kattar, S, Kleinschek, M.A, Leccese, E, Lesburg, C, Li, C, Lim, J, Liu, D, Maclean, J.K.F, Mansoor, F, Moy, L.Y, Mulrooney, E.F, Necheva, A.S, Presland, J, Rakhilina, L, Yang, R, Torres, L, Zhang-Hoover, J, Northrup, A.Show

Bioorg. Med. Chem. Lett. 27 2721 2726 (2017)

PMID: 28501511 DOI: 10.1016/j.bmcl.2017.04.050

Abstact

Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. Medicinal chemistry optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity. These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures